WO1999061072A3 - Procedes d'inhibition de la formation de caillots - Google Patents

Procedes d'inhibition de la formation de caillots Download PDF

Info

Publication number
WO1999061072A3
WO1999061072A3 PCT/US1999/011843 US9911843W WO9961072A3 WO 1999061072 A3 WO1999061072 A3 WO 1999061072A3 US 9911843 W US9911843 W US 9911843W WO 9961072 A3 WO9961072 A3 WO 9961072A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
clot formation
inhibiting clot
inhibiting
α2ap
Prior art date
Application number
PCT/US1999/011843
Other languages
English (en)
Other versions
WO1999061072A2 (fr
Inventor
Guy L Reed
Original Assignee
Harvard College
Guy L Reed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Guy L Reed filed Critical Harvard College
Priority to JP2000550531A priority Critical patent/JP2002516296A/ja
Priority to EP99953293A priority patent/EP1079866A2/fr
Priority to CA002333592A priority patent/CA2333592A1/fr
Priority to AU63092/99A priority patent/AU761869B2/en
Publication of WO1999061072A2 publication Critical patent/WO1999061072A2/fr
Publication of WO1999061072A3 publication Critical patent/WO1999061072A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur des procédés de détection de caillots sanguins in vivo et sur des procédés visant à inhiber la formation de caillots et faciliter la thrombolyse à l'aide de polypeptides antiplasmine alpha-2 (α2AP).
PCT/US1999/011843 1998-05-29 1999-05-28 Procedes d'inhibition de la formation de caillots WO1999061072A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000550531A JP2002516296A (ja) 1998-05-29 1999-05-28 凝塊形成を阻害する方法
EP99953293A EP1079866A2 (fr) 1998-05-29 1999-05-28 Procedes d'inhibition de la formation de caillots
CA002333592A CA2333592A1 (fr) 1998-05-29 1999-05-28 Procedes d'inhibition de la formation de caillots
AU63092/99A AU761869B2 (en) 1998-05-29 1999-05-28 Methods of inhibiting clot formation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8721898P 1998-05-29 1998-05-29
US60/087,218 1998-05-29

Publications (2)

Publication Number Publication Date
WO1999061072A2 WO1999061072A2 (fr) 1999-12-02
WO1999061072A3 true WO1999061072A3 (fr) 2000-04-13

Family

ID=22203808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011843 WO1999061072A2 (fr) 1998-05-29 1999-05-28 Procedes d'inhibition de la formation de caillots

Country Status (5)

Country Link
US (1) US6534035B1 (fr)
EP (1) EP1079866A2 (fr)
JP (1) JP2002516296A (fr)
AU (1) AU761869B2 (fr)
WO (1) WO1999061072A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002054088A2 (fr) * 2001-01-05 2002-07-11 Duke University Agent ameliorateur de contraste en imagerie par resonance magnetique
US7056286B2 (en) 2003-11-12 2006-06-06 Adrian Ravenscroft Medical device anchor and delivery system
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
US9150903B2 (en) * 2007-04-25 2015-10-06 Translational Sciences Inc. Method of increasing plasmin activity through antiplasmin conversion
WO2010071788A1 (fr) * 2008-12-17 2010-06-24 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Marqueurs du cancer du pancréas et leurs utilisations
WO2011056981A2 (fr) 2009-11-04 2011-05-12 Nitinol Devices And Components, Inc. Conception de stent de pontage périphérique alternatif et procédé pour son utilisation
WO2012047308A1 (fr) 2010-10-08 2012-04-12 Nitinol Devices And Components, Inc. Autre conception d'endoprothèse vasculaire de pont circonférentielle et ses procédés d'utilisation
AU2012304635B2 (en) 2011-09-06 2017-08-31 Translational Sciences Inc. SerpinF2-binding molecules and methods of use
WO2016106186A1 (fr) 2014-12-22 2016-06-30 Translational Sciences, Inc. Prophylaxie de la thrombose

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000051A1 (fr) * 1987-07-07 1989-01-12 Cytrx Biopool Ltd. Compose se liant a la fibrine et procede
EP0358160A2 (fr) * 1988-09-05 1990-03-14 Teijin Limited Protéine ayant une activité inhibitrice de la plasmine humaine
WO1994004702A2 (fr) * 1992-08-21 1994-03-03 Immunomedics, Inc. Procede ameliore de detection et de therapie de lesions au moyen de conjugues de biotine ou d'avidine
WO1996001653A1 (fr) * 1994-07-11 1996-01-25 Board Of Regents, The University Of Texas System Procedes et compositions pour la coagulation specifique de vaisseaux
US5679320A (en) * 1988-12-29 1997-10-21 Bio-Technology General Corp. Fibrin binding domain polypeptides and uses and methods of producing same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000051A1 (fr) * 1987-07-07 1989-01-12 Cytrx Biopool Ltd. Compose se liant a la fibrine et procede
EP0358160A2 (fr) * 1988-09-05 1990-03-14 Teijin Limited Protéine ayant une activité inhibitrice de la plasmine humaine
US5679320A (en) * 1988-12-29 1997-10-21 Bio-Technology General Corp. Fibrin binding domain polypeptides and uses and methods of producing same
WO1994004702A2 (fr) * 1992-08-21 1994-03-03 Immunomedics, Inc. Procede ameliore de detection et de therapie de lesions au moyen de conjugues de biotine ou d'avidine
WO1996001653A1 (fr) * 1994-07-11 1996-01-25 Board Of Regents, The University Of Texas System Procedes et compositions pour la coagulation specifique de vaisseaux

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD COAGULATION FIBRINOLYSIS (1995), 6(5), 481-5 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; UDVARDY, M. ET AL: "RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptid (RGDF coupled with the carboxy terminal part of.alpha.2-antiplasmin) enhances plasminogen binding to platelets", XP002124573, retrieved from STN Database accession no. 123:218018 *

Also Published As

Publication number Publication date
EP1079866A2 (fr) 2001-03-07
WO1999061072A2 (fr) 1999-12-02
AU6309299A (en) 1999-12-13
AU761869B2 (en) 2003-06-12
JP2002516296A (ja) 2002-06-04
US6534035B1 (en) 2003-03-18

Similar Documents

Publication Publication Date Title
IL140939A0 (en) Inhibitors of urokinase and blood vessel formation
WO1995021601A3 (fr) Proteines de 'domaine de kunitz' a activite antikallikreine, et leurs analogues
AU4941101A (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
EP1031830B8 (fr) Système électrochimique pour la détermination d'un temps de coagulation du sang
IL144401A0 (en) System and method for noninvasive blood analyte measurements
WO2005020790A3 (fr) Techniques et systemes automatises de detection et d'analyse de plaque vasculaire
AU3083301A (en) Improved tissue engineered blood vessels and methods and apparatus for their manufacture
MXPA03007816A (es) Calzoncillo desechable y metodo para proporcionar el mismo.
AU7466300A (en) Method and apparatus for detecting blood characteristics including hemoglobin
NO20000268L (no) Anvendelse av Lactobacillus for reduksjon av fibrinogen nivå i blod
WO1999061072A3 (fr) Procedes d'inhibition de la formation de caillots
WO2000013703A3 (fr) Methodes de traitement de l'hypertension et compositions utiles a cet effet
ZA964762B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
WO2003031650A3 (fr) Genes et proteines utilises dans la prevention, la prediction, le pronostic et la therapie de la maladie cardiovasculaire
WO2003031585A3 (fr) Molecules d'acide nucleique codant une serine protease transmembranaire 25, polypeptides codes et procedes connexes
WO2002100337A3 (fr) Variantes antithrombotiques de la thrombine
AU6539000A (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
AU2002316162A1 (en) Method of increasing anti-neugc antibody levels in blood
ZA971419B (en) Macrocyclic peptides useful in the treatment of thrombin related disorders
WO2002044328A3 (fr) Polypeptides anti-angiogeniques
AU3460800A (en) Method of bleaching blood samples, diagnostic method and diagnostic kit using the same
AU2001240820A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
ZA200207590B (en) Production of recombinant blood clotting factors in human cell lines.
AU2974300A (en) Plasminogen kringle 4 region fragments and methods of use
WO2002018633A3 (fr) Determination de la capacite des patients de reagir a un traitement des tumeurs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 63092

Kind code of ref document: A

Format of ref document f/p: F

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 550531

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2333592

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 63092/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999953293

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999953293

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 63092/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999953293

Country of ref document: EP